|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Allergy and Infectious Diseases (NIAID) <https://www.niaid.nih.gov/> For Immediate Release: Thursday, October 31, 2024 CONTACT: NIAID News & Science Writing Branch, (301) 402-1663, <email:niaidnews@xxxxxxxxxxxxx> MEDIA AVAILABILITY NIH TRIAL OF RECTAL MICROBICIDE FOR HIV PREVENTION BEGINS IN THE UNITED STATES Study will assess safety and acceptability of rectal douche for pre-exposure prophylaxis WHAT: A clinical trial sponsored by the National Institutes of Health (NIH) has launched to examine the safety and acceptability of a novel rectal HIV microbicide douche containing the antiretroviral drug tenofovir. This “on-demand” HIV prevention
approach involves using the microbicide prior to a potential exposure from receptive anal intercourse.
Several forms of HIV pre-exposure prophylaxis (PrEP) are in use in the United States and globally, namely daily oral pills, long-acting injections, and a monthly vaginal ring. The Centers for Disease Control and Prevention advises that
gay, bisexual and other men who have sex with men who meet certain criteria can take “on-demand” oral PrEP <https://www.cdc.gov/hivnexus/hcp/prep/index.html> around the time of sex to prevent HIV acquisition, but there is insufficient evidence to support its
use in other populations. Rectal microbicides are another HIV prevention method being explored for use in an “on-demand” manner to expand the choices available to eligible people who engage in receptive anal intercourse and who stand to benefit from using
PrEP. The clinical trial will enroll about 150 adults assigned male at birth who have regular experience using an unmedicated rectal douche before receptive anal intercourse. Participants will each receive “on-demand” tenofovir rectal microbicide
douche during one two-month period and on-demand oral PrEP with tenofovir disoproxil fumarate and emtricitabine in another two-month period. All participants will be monitored closely for safety. The study also will assess participants’ experience using their
assigned PrEP method, including measures of acceptability, adherence, and method preference. The study will take place at eight sites in the United States. While HIV incidence is slowly decreasing in the United States < https://stacks.cdc.gov/view/cdc/156513>, 67% of U.S. HIV diagnoses from 2018-2022 were among gay, bisexual, and other men who have sex with men, pointing to the need for expanded
HIV prevention options. The mid-stage study is sponsored NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and implemented through the NIH-funded HIV Prevention Trials Network (HPTN). NIH remains committed to developing safe and effective
HIV prevention methods that people need, want, and are able to use. More information about this study, also known as HPTN 106, is available at ClinicalTrials.gov under identifier NCT06560684 <https://clinicaltrials.gov/study/NCT06560684>. WHO: Sheryl Zwerski, D.N.P., director of the Prevention Sciences Program in NIAID’s Division of AIDS, is available to discuss this research. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.
News releases, fact sheets and other NIAID-related materials are available on the NIAID website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: <https://www.nih.gov/news-events/news-releases/nih-trial-rectal-microbicide-hiv-prevention-begins-united-states> To subscribe (or unsubscribe) from NIH News Release mailings, go to <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
